News
30 Sep 2020
BioVectra Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities
BioVectra Inc., a global Contract Development and Manufacturing Organization (CDMO), today announced new investments in its large-scale synthetic chemistry and analytical development capabilities. To continue serving its client’s cGMP manufacturing needs, BioVectra completed the replacement of two 4,000L vessels used for small molecule synthesis.
Mentioned Companies
BioVectra Inc.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance